Meanwhile, Hsu Ming-chu, president of TaiGen, stresses how valuable imported technologies can be, noting that TaiGen has introduced techniques for activating receptor genes from the United States-techniques which can be used to develop new drugs for treating cancer and chronic infections such as hepatitis.
而太景生技總經理許明珠則指出，太景將於三年內自美國引進活化的基因受體技術，來進行癌症與慢性發炎症的新藥研究，尤其是亞洲高發性的肝炎，更是重點。